I. Call to Order…………………………………………………………………………………………Marty McKay

II. Parliamentary Business ……………………………………………………………Marty McKay
   A. Introduction of Members/Roll Call

III. P & T Committee Review Virtual Process…………………..Hind Douiki/Melwyn Wendt

IV. Reports…………………………………………………………..………..Melwyn Wendt
   A. PDL Reflecting Spring 2021 Recommendations

V. New Business…………………………………………………………………………………………Hind Douiki
   A. Explanation of TOPS, Monographs and Cost Sheet
   B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony/Public Testimony
      1. Alzheimer’s Agents
      2. Anthelmintics
      3. Anti-Allergens, Oral
      4. Anticonvulsants
      5. Antidepressants, Other
      6. Antidepressants, SSRIs
      7. Antihistamines, Minimally Sedating
      8. Antihypertensives, Sympatholytics
      9. Antihyperuricemics
      10. Antiparkinson’s Agents
      11. Antipsoritics, Oral
      12. Antipsoritics, Topical
      13. Antipsychotics
      14. Anxiolytics
      15. Bile Salts
      16. Botulinum Toxins
      17. Bronchodilators, Beta Agonist
      18. Colony Stimulating Factors
      19. COPD Agents
      20. Cytokine and CAM Antagonists
      21. Emollients
      22. Enzyme Replacement, Gauchers Disease
      23. Epinephrine, Self-Injected
24. Erythropoiesis Stimulating Proteins
25. Glucocorticoids, Inhaled
26. Glucocorticoids, Oral
27. Hemophilia Treatment
28. Histamine II Receptor Blocker
29. Idiopathic Pulmonary Fibrosis
30. Immune Globulins
31. Immunomodulators, Asthma
32. Immunomodulators, Atopic Dermatitis
33. Immunomodulators, Lupus - New
34. Immunomodulators, Topical
35. Intranasal Rhinitis Agents
36. Leukotriene Modifiers
37. Methotrexate
38. Movement Disorders
39. Neuropathic Pain
40. NSAIDs
41. Oncology Oral – Breast
42. Oncology Oral – Hematologic
43. Oncology Oral - Lung
44. Oncology Oral – Other
45. Oncology Oral – Prostate
46. Oncology Oral – Renal Cell
47. Oncology Oral - Skin
48. Ophthalmic Antibiotics
49. Ophthalmic, Antimicrobial-Steroid Combinations
50. Ophthalmics for Allergic Conjunctivitis
51. Ophthalmics, Anti-Inflammatory
52. Ophthalmics, Anti-Inflammatory/Immunomodulator
53. Ophthalmics, Cystinosis - New
54. Ophthalmics, Glaucoma Agents
55. Otic Antibiotics
56. Otic Anti-Infective & Anesthetics
57. Progestational Agents
58. Sedative Hypnotics
59. Sickle Cell Anemia Treatments
60. Smoking Cessation
61. Steroids, Topical High
62. Steroids, Topical Low
63. Steroids, Topical Medium
64. Steroids, Topical Very High
65. Stimulants and Related Agents
66. Thrombopoiesis Stimulating Proteins

VI. New & Other Single Drug Reviews………………………………………………Hind Douiki
67. Antifungals, Oral - Brexafemme®
68. Bladder Relaxant Preparations – Myrbetriq® Granules
69. Glucagon Agents – Zegalog® Syringe
70. Glucagon Agents – Zegalog® Autoinjector
71. Multiple Sclerosis Agents – Ponvory® Starter Pack
72. Multiple Sclerosis Agents – Ponvory® Tablet
73. Opiate Dependence Treatments – Kloxxado® Spray
74. Phosphate Binders – Magnebind® 400 RX
75. Uterine Disorder Treatments - Myfembree®

VII. Other Business

VIII. Next Steps
   A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – Friday, April 29, 2022 or Friday, May 6, 2022

X. Public Testimony